Document text
Principal Investigator: OFER LEVY
Organization: BOSTON CHILDREN'S HOSPITAL
Fiscal Year: 2020
Award: $2,174,014
Funding agency: National Institute of Allergy and Infectious Diseases
Project Summary/Abstract
In Dec 2019, a cluster of respiratory illness in Wuhan China defined the onset of a worldwide pandemic involving
a novel coronavirus (SARS-CoV-2). SARS-CoV-2 infected patients are frequently asymptomatic, but initial
epidemiologic estimates from the WHO indicate that ~15% of patients develop severe disease including viral
pneumonia often requiring ICU care due to progression to develop life-threatening complications including (but
not limited to) shock and secondary organ failures, and super-infections. Risk factors for increased mortality from
COVID-19 include older age, COPD, ischemic heart disease, diabetes mellitus, and immunosuppression.
Although direly needed, no targeted therapies or vaccinations are available as of now. Major research efforts
have been launched towards the development of anti-SARS-CoV-2 vaccines, including those within Boston
Children’s Hospital’s Precision Vaccines Program. To facilitate and accelerate these therapy and vaccination
development efforts, more detailed immunophenotyping and understanding of the host immune response to
SARS-CoV-2 are required. This knowledge may inform prognostication of resolution of infection versus disease
progression and identify the relevant targets for potential therapeutic interventions. Overall, the outcomes of
these immunophenotyping maps are critical for identifying and prioritizing host-directed interventions to limit or
mitigate disease progression. Based on this rationale, we hypothesize that plasma proteomics and metabolomics
from hospitalized COVID-19 patients, longitudinally collected during the hospital stay and during the subsequent
convalescence period of up to one year post-discharge from the hospital will provide much needed insights into
the intricacies of the immunophenotype of COVD19 patients. Thus, they will be crucial to support NIAID’s efforts
towards enabling and accelerating therapy and vaccine development. To this end, we propose a Proteomics and
Metabolomics Core (PMC) to support NIAID’s efforts to characterize at the molecular and cellular level the
immunophenotype associated with COVID-19.
The PMC will quantitative map the global plasma proteome (Specific Aim 1) and the global plasma metabolome
(Specific Aim 2), followed by hypothesis-driven targeted metabolomics to detect metabolites and metabolic
pathways that play a role in the COVID-19 disease progression (Specific Aim 3). All plasma samples will be
longitudinally collected from COVID-19 patients upon hospitalization and the following 28 days in the hospital as
well as the subsequent convalescence period of up to 12 months after discharge.
We anticipate that the PMC will make substantial contributions to confronting the new COVID-19 pandemic, for
which therapeutic strategies and vaccines must be developed rapidly. The PMC will help portray a broad profile
of the changes that occur in COVID-19 patients and that are associated with disease severity, progression and
recovery to support the quest for anti-COVID-19 therapies and vaccines.
Terms: <2019 novel coronavirus><2019-nCoV><Aching muscles><Age><Antiviral Agents><Antiviral Drugs><Antivirals><Award><Biological Markers><Blood Plasma><Boston><COPD><COVID-19><COVID-19 epidemic><COVID-19 pandemic><COVID19><COVID19 epidemic><COVID19 pandemic><Caring><Cellular Immune Function><Children's Hospital><China><Chronic Obstruction Pulmonary Disease><Chronic Obstructive Airway Disease><Chronic Obstructive Lung Disease><Chronic Obstructive Pulmonary Disease><Circulatory Collapse><Clinical><Clinical Trials><CoV emergence><Collaborations><Controlled Clinical Trials><Convalescence><Coronaviridae><Coronavirus><Coughing><Development><Diabetes Mellitus><Diagnostic><Disease><Disease Outcome><Disease Progression><Disorder><Epidemiology><Fever><Hospital Admission><Hospitalization><Hospitals><Human><Immune response><Immune system><Immunochemical Immunologic><Immunologic><Immunologic Subtyping><Immunological><Immunological response><Immunologically><Immunologics><Immunophenotyping><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Infection><Intervention><Intervention Strategies><Investigation><Ischemic Heart><Ischemic Heart Disease><Ischemic myocardium><Knowledge><LC/MS><Label><Lead><Length of Stay><Life><Literature><Mainland China><Malaise><Maps><Mass Photometry/Spectrum Analysis><Mass Spectrometry><Mass Spectroscopy><Mass Spectrum><Mass Spectrum Analyses><Mass Spectrum Analysis><Metabolic Pathway><Microbial Superinvasion><Modern Man><Molecular><Morbidity><Morbidity - disease rate><Muscle discomfort><Muscle pain><Muscle pain/fibrositis><Muscle sorenesss><Myalgia><Myalgic><Myocardial Ischemia><Myodynia><Myoneuralgia><Myosalgia><NIAID><National Institute of Allergy and Infectious Disease><Number of Days in Hospital><Onset of illness><Organ failure><Outcome><Parents><Patients><Pb element><Pediatric Hospitals><Plasma><Plasma Proteins><Plasma Serum><Play><Population><Preventative strategy><Prevention strategy><Preventive strategy><Proteome><Proteomics><Pyrexia><Randomized Controlled Trials><Recovery><Reporting><Reproducibility><Research><Resolution><Reticuloendothelial System, Serum, Plasma><Risk Factors><Role><SARS-CoV-2><SARS-CoV2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Sampling><Severe acute respiratory syndrome coronavirus 2><Severity of illness><Shock><Technology><Testing><Therapeutic><Therapeutic Agents><Therapeutic Intervention><Vaccination><Vaccines><Validation><Viral Pneumonia><Viral Respiratory Tract Infection><Virus><Wuhan coronavirus><age group><ages><allergic/immunologic body system><allergic/immunologic organ system><anti-viral agents><anti-viral drugs><anti-virals><base><bio-markers><biologic marker><biomarker><cardiac ischemia><circulatory shock><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronary ischemia><coronavirus disease 2019><coronavirus disease 2019 epidemic><coronavirus disease 2019 pandemic><coronavirus emergence><develop a vaccine><develop therapy><development of a vaccine><developmental><diabetes><disease onset><disease severity><disorder onset><emergent CoV><emergent coronavirus><emerging CoV><emerging coronavirus><epidemiologic><epidemiological><febrile><febris><heart ischemia><heavy metal Pb><heavy metal lead><hospital days><hospital length of stay><hospital stay><host response><immune function><immune suppression><immunogenicity><immunological status><immunophenotype><immunoresponse><insight><interest><intervention development><intervention therapy><interventional strategy><liquid chromatography mass spectrometry><metabolism measurement><metabolome><metabolomics><metabonome><metabonomics><mortality><myocardial ischemia/hypoxia><myocardium ischemia><nCoV><new CoV><new approaches><new coronavirus><novel><novel CoV><novel approaches><novel coronavirus><novel strategies><novel strategy><off-label application><off-label prescribing><off-label use><pandemic><pandemic disease><pathogen><patient subgroups><patient subpopulations><patient subsets><patient subtypes><prognostic><programs><respiratory><response><social role><super infection><superinfection><targeted biomarker><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapy development><treatment development><treatment strategy><vaccine development><vaccine formulation><viral respiratory infection>